Savara Inc
NASDAQ:SVRA
Savara Inc
Pre-Tax Income
Savara Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Pre-Tax Income
-$82.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$3.7B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$690m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$248.5m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Pre-Tax Income?
Pre-Tax Income
-82.9m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Pre-Tax Income amounts to -82.9m USD.
What is Savara Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-12%
Over the last year, the Pre-Tax Income growth was -70%. The average annual Pre-Tax Income growth rates for Savara Inc have been -22% over the past three years , -7% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet